The AlivaMab Mouse, developed by Ablexis, is a best-in-class transgenic platform that is currently licensed to eight of the top 15 pharma, such as Novartis, Pfizer, Janssen and Boehringer Ingelheim, as well as other biopharma companies. The design of the AlivaMab Mouse supports successful antibody drug discovery and development through robust immune responses that are diverse in sequence and epitope recognition, yielding antibodies with high affinity, potency, specificity and developability. The AlivaMab Mouse is available for licensing on a non-exclusive basis through Ablexis, but for those companies interested in out-sourcing, access to the AlivaMab Mouse platform is also available through AlivaMab Discovery Services (ADS). Through our extensive experience and capabilities, in combination with the AlivaMab Mouse, our team of experts provide pharma and biotech companies the foundation for a streamlined and de-risked path from discovery to development through to commercialization.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):